...
首页> 外文期刊>International Journal of Clinical and Experimental Pathology >Mixed lineage kinase domain-like protein is a prognostic biomarker for cervical squamous cell cancer
【24h】

Mixed lineage kinase domain-like protein is a prognostic biomarker for cervical squamous cell cancer

机译:混合谱系激酶域样蛋白是宫颈鳞状细胞癌的预后生物标志物

获取原文

摘要

Background: The mixed lineage kinase domain-like protein (MLKL) has recently been identified as a key RIP3 (receptor interacting protein 3) downstream component of tumor necrosis factor (TNF)-induced necroptosis. Objective: To evaluate the expression and clinical significance of MLKL in cervical squamous cell carcinoma.Methods: The expression of MLKL in 54 cervical squamous carcinoma samples was detected by immuneohistochemical method. Chi-square, correlation analysis and kaplan-Meier method were used to analyze the data. Results: The MLKL expression in cervical squamous cell carcinoma was higher than that in normal cervical tissues (P = 0.004). The MLKL expression was negatively correlated with histological grade, lymphatic metastasis (P<0.05). Survival analysis showed the low expression of MLKL indicated poor prognosis. Conclusion: MLKL was a prognostic biomarker for cervical squamous cell carcinoma.
机译:背景:混合谱系激酶域样蛋白(MLKL)最近已被确定为肿瘤坏死因子(TNF)诱导的坏死病的关键RIP3(受体相互作用蛋白3)下游成分。目的:探讨MLKL在宫颈鳞癌中的表达及其临床意义。方法:采用免疫组织化学方法检测54例宫颈鳞癌中MLKL的表达。采用卡方检验,相关分析和Kaplan-Meier法对数据进行分析。结果:子宫颈鳞状细胞癌中MLKL的表达高于正常子宫颈组织(P = 0.004)。 MLKL表达与组织学分级,淋巴结转移呈负相关(P <0.05)。生存分析表明MLKL的低表达提示预后不良。结论:MLKL是宫颈鳞状细胞癌的预后生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号